Tower Research Capital LLC (Trc) Aptevo Therapeutics Inc. Transaction History

Tower Research Capital LLC (Trc)

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$0.17 - $0.38 $28 - $62	165 Added 1.22%	13,660 $2,000
Q3 2023 Nov 14, 2023	BUY	$0.31 - $1.78 $3,721 - $21,368	12,005 Added 805.7%	13,495 $4,000
Q2 2023 Aug 14, 2023	BUY	$1.34 - $2.08 $1,996 - $3,099	1,490 New	1,490 $2,000
Q4 2022 Feb 10, 2023	SELL	$2.0 - $138.16 $5,390 - $372,341	-2,695 Reduced 95.98%	113 $0
Q3 2022 Nov 10, 2022	BUY	$3.12 - $142.56 $8,760 - $400,308	2,808 New	2,808 $9,000
Q4 2021 Feb 14, 2022	SELL	$6.48 - $17.49 $7,737 - $20,883	-1,194 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$15.01 - $22.16 $17,921 - $26,459	1,194 New	1,194 $18,000
Q2 2021 Aug 16, 2021	SELL	$21.85 - $30.0 $3,059 - $4,200	-140 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$27.86 - $40.59 $2,841 - $4,140	-102 Reduced 42.15%	140 $4,000
Q4 2020 Feb 16, 2021	BUY	$6.21 - $48.36 $1,502 - $11,703	242 New	242 $9,000
Q3 2020 Nov 16, 2020	SELL	$7.21 - $9.37 $17,635 - $22,919	-2,446 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$3.11 - $9.27 $6,723 - $20,041	2,162 Added 761.27%	2,446 $20,000
Q1 2020 May 15, 2020	BUY	$3.29 - $9.73 $934 - $2,763	284 New	284 $1,000

Ticker APVO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 5,090,640
Market Cap $24.2M
Description
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelo...

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.